MyoContract is developing neuromuscular disease therapeutics.

History:

MyoContract was founded in 2001 and merged with Graffinity Pharmaceuticals in 2004 to become Santhera Pharmaceuticals.

Employment

Email:

Fax:

Mail:

General Info:

Ticker:

Employees:

Regions:
Europe

Research Focus:
Disease Therapeutics-Research Therapeutics-Development Therapeutics-Clinical early (I, II)

 

Profiles:

 

News:

Keywords: 

Strategic Partnerships: